TrialReader


A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor

NCT04796285 — Not applicable, Active not recruiting, 6 participants, Brigham and Women's Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04796285
StatusActive not recruiting
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, diagnostic
Enrollment6 (Actual)
SponsorBrigham and Women's Hospital (Other); collaborators: Cambridge Medical Technologies, LLC
ConditionsSepsis, Sepsis Bacterial, Lactate Blood Increase, Infectious Disease
InterventionsLab Clasp (Device)
Datesstart 2022-08-01, primary completion 2026-12-01 (estimated), completion 2026-12-01 (estimated), first posted 2021-03-12, last updated 2026-07-16
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Sepsis All trials for Sepsis Bacterial All trials of Lab Clasp

-Summary

The overall purpose of this study is to demonstrate the usability of a clinical-grade device in the form of a finger clasp similar to a pulse oximeter for monitoring lactate values, by comparing its performance in reading interstitial fluid lactate values against a known clinical standard in the form of venous lactate levels.

Serum lactate measurements are used clinically as a measure of end-organ dysfunction and physiologic stress. Changes in lactate may indicate worsening infection in the setting of sepsis, drug toxicity for certain xenobiotics, or exercise tolerance in exercise physiology. Serum lactate cutoffs have been developed for various disease states and trigger a variety of medical decisions directed at managing the course of the disease.

A common theme in the application of lactate measurements to understanding changes in physiology is the need to obtain venous blood to determine lactate. While point-of-care assays have been developed that improve the processing speed, there continues to be a need to obtain fingerstick blood or in most cases, venous blood. Obtaining venous blood for serum lactate requires an individual with phlebotomy skills, the processing capabilities of a laboratory to determine lactate concentrations, or the availability of point of care technology.

An alternative method to measure lactate is to sample interstitial fluid which surrounds cells and tissues in the body. Obtaining interstitial fluid is potentially less invasive without the need for repeat phlebotomy or the presence of an indwelling intravenous catheter which can become complicated by infection. The analysis of interstitial fluid for glucose has been validated and is clinically utilized in continuous glucose monitors in individuals with diabetes. In this investigation, the investigators will utilize a novel device, the Lab Clasp to obtain interstitial fluid in a noninvasive method. The Lab Clasp is manufactured to resemble a finger pulse oximeter with additional onboard microfluidics channels that obtain a lactate concentration from interstitial fluid. This streamlined process of obtaining the point of care lactate measurements on demand allows for tasks like serial lactate measurements to be accomplished on a reliable schedule with less workload for nursing staff typically required to draw venous blood. Additionally, the portable and noninvasive nature of the Lab Clasp system may render it usable in facilities that lack skilled staff necessary to perform phlebotomy.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Lab ClaspExperimentalDevice: Lab ClaspA finger based device to assay interstitial fluid lactate
  • Lab Clasp (Device): Finger-based interstitial fluid assessment device

+Outcome measures

Primary outcomes

  • Comparison of average difference lactate readings between Lab Clasp and laboratory reference values. [150 minutes]: The primary outcome measure will be the average difference in lactate values between the Lab Clasp device and the reference (laboratory venous lactate) in healthy volunteers. We will obtain multiple (nine timepoints in total) investigational-reference measurement pairs in each subject (150 minutes total) and will average the difference over all pairs from all subjects.

Secondary outcomes

  • Measurement of participant experience [150 minutes]: We will give each participant a questionnaire when they finish their visit and will ask for their experience (Likert-type scale, 1-5)

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria

1. Are 18 years or older
2. In general good health, evidenced by no unstable medical problems (no medication changes in the past 3 months)
3. Have no known skin allergy to the components of the Lab Clasp
4. Willing to comply with all study procedures including providing venous blood samples at the CCI
5. Are English speaking
6. Provide consent to participate in the study

Exclusion Criteria:

1. Individuals <18 years old
2. General frailty of health
3. Prohibitively poor vascular access
4. History of malignancy or active malignancy
5. History of cardiac illness
6. History of HIV on antiretrovirals
7. History of alcohol abuse
8. History of uncontrolled psychiatric illness
9. Recent hospitalization within the past 30 days
10. History of vaping, propylene glycol use
11. History of statin use
12. Non-English speaking
13. Pregnant women, children, vulnerable populations
14. Investigator discretion for suspicion of poor study compliance

+Locations (1)

FacilityCityCountryStatus
Brigham and Women's HospitalBoston, MassachusettsUnited States

+Investigators

My Notes